Patients with CHF have a high risk of developing pAF (24.4%). 75% of patients with AF do not feel the development of paroxysm. All CHF patients should undergo EchoCG with assessment of LA EF, TDI E med and LA GS to identify a group at risk for the development of AF. Heart rhythm remote monitoring with CardioQVARK® devices can be considered a reliable method for early detection of pAF and timely initiation of anticoagulant therapy in patients with CHF.
Keyphrases
- atrial fibrillation
- catheter ablation
- oral anticoagulants
- ejection fraction
- left atrial
- left atrial appendage
- direct oral anticoagulants
- heart failure
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- percutaneous coronary intervention
- prognostic factors
- stem cells
- venous thromboembolism
- patient reported outcomes
- mesenchymal stem cells
- patient reported